Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Andera Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Andera Partners

Andera Partners

Operating

Andera Partners: A French investment firm specializing in innovative small and mid-cap companies.

Location
Paris, Paris, FR
Founded
2002
Firm
Compare
Portfolio
Fundraising
Employees
Website

Andera Partners is a French investment firm specializing in innovative small and mid-cap companies. The firm typically engages in Series A to Series D investment rounds, focusing on sectors that require substantial innovation and development. Andera Partners supports companies primarily within France, aiming to foster sustainable growth and adaptation in a rapidly changing business environment.

Notable portfolio companies include Avalyn Pharma, Bioventrix, Complexa, Evommune, Genoa Pharmaceuticals, Ipside, Realeve, and Santen Ventures. The firm is led by key partners who emphasize strong partnerships and collaborative growth strategies. Andera Partners offers unique value-add services to its portfolio companies, ensuring they have the right support to navigate challenges and achieve long-term success.

Andera Partners - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments12
Current Portfolio Count7
Total Portfolio Exits1

Top Investment Stages

Series A4 (36.4%)
Post Ipo Equity3 (27.3%)
Series D2 (18.2%)
Series B1 (9.1%)
Series C1 (9.1%)

Stage Mix

Series A 36%Post Ipo Equity 27%Series D 18%Series B 9%Series C 9%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Evommune logo

Evommune

Bioventrix logo

Bioventrix

Complexa logo

Complexa

Genoa Pharmaceuticals logo

Genoa Pharmaceuticals

Avalyn Pharma logo

Avalyn Pharma

Ipside logo

Ipside

Realeve logo

Realeve

Santen Ventures logo

Santen Ventures

Andera Partners - Classification

NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
ISIC
  • 6430Trusts, funds and similar financial entities
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end